BioStock: Scandion Oncology comments on the technical delay with SOM-101

Today, Scandion Oncology announced that the company has identified novel analogues with more than tenfold higher potency against antibiotic resistant bacteria than the original compound, and that the in vivo animal study has been delayed from Q4 2019 until Q1 2020 due to technical issues with the control substance. BioStock reached out to the company for a comment.

Läs hela artikeln på biostock.se: 

https://www.biostock.se/2019/12/scandion-oncology-comments-on-the-technical-delay-with-som-101/

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se